June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Reduction of macular pigment as early feature of Tamoxifen retinopathy: a pilot study.
Author Affiliations & Notes
  • Chiara Preziosa
    Sacco Hospital, Eye Clinic, University of Milan, Milan, Italy
  • Isabella D'Agostino
    Sacco Hospital, Eye Clinic, University of Milan, Milan, Italy
  • Ugo Nava
    Sacco Hospital, Eye Clinic, University of Milan, Milan, Italy
  • Mariano Cozzi
    Sacco Hospital, Eye Clinic, University of Milan, Milan, Italy
  • Mario V Cigada
    Sacco Hospital, Eye Clinic, University of Milan, Milan, Italy
  • Marco Pellegrini
    Sacco Hospital, Eye Clinic, University of Milan, Milan, Italy
  • Giovanni Staurenghi
    Sacco Hospital, Eye Clinic, University of Milan, Milan, Italy
  • Footnotes
    Commercial Relationships   Chiara Preziosa, None; Isabella D'Agostino, None; Ugo Nava, None; Mariano Cozzi, Alcon (F), Bayer (F), Heidelberg Engeneering (F); Mario Cigada, None; Marco Pellegrini, Optovue (R); Giovanni Staurenghi, Alcon (C), Alcon (R), Allergan (C), Bayer (C), Bayer (R), Boehringer Ingelheim (C), Genentec (C), Heidelberg Engineering (C), Heidelberg Engineering (R), Novartis (F), Novartis (C), Novartis (R), Ocular Instrument (P), Optos (C), Optovue (F), Roche (C), Zeiss (F), Zeiss (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5167. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Chiara Preziosa, Isabella D'Agostino, Ugo Nava, Mariano Cozzi, Mario V Cigada, Marco Pellegrini, Giovanni Staurenghi; Reduction of macular pigment as early feature of Tamoxifen retinopathy: a pilot study.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5167.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Tamoxifen retinopathy is a condition characterized by cavitations occurring in the central macula at Spectral Domain - Optical Coherence Tomography (SD-OCT) imaging; these alterations appear similar to changes occurring in macular telangiectasia type 2 where a reduction of macular pigment has been already established with toxicity primarily affecting retinal Muller cells. In this study we investigated macular pigment density in patients treated with Tamoxifen for breast cancer.

Methods : A transversal observational study to compare the macular pigment optical density (MPOD) in 30 patients treated with Tamoxifen (20 mg daily) and 16 healthy subjects matched by age. The MPOD was measured by means of the two-wavelengths autofluorescence (AF) technique (488 and 514 nm) using the Heidelberg HRA + OCT Spectralis (Heidelberg Engineering, Heidelberg, Germany). MPOD maps were generated by automatic subtraction of the log AF images using the inbuilt Eye Explorer software (HEYEX).

Results : Mean MPOD at peak was 0,69 ± 0,18 density units (DU) and 0,78 ± 0,14 respectively in Tamoxifen and control group (P = 0,07). In Tamoxifen group the mean MPOD at 0,5° eccentricity was 0,58 ± 0,14, at 1° was 0,54 ± 0,13 and at 2° was 0,34 ± 0,1 while in the control group it was 0,62 ± 0,16 at 0,5° eccentricity, 0,55 ± 0,13 at 1° and 0,32 ± 0,06 at 2° (P > 0,05). The radius at half peak of MPOD was located at 1,4 and 1,1 degrees from fovea respectively in Tamoxifen group and in healthy subjects (P = 0,0076). A linear regression investigated the relation between the duration of treatment (mean 32 months, min 10 max 60) and the MPOD at peak, showing a weak inverse correlation (r = -0,35, P = 0,051).

Conclusions : In our series patients treated with Tamoxifen likely showed a reduction of MPOD levels at peak, 0,5° and 1° eccentricity compared to control group; nevertheless these differences were not statistically significant. The radius at half peak of MPOD in Tamoxifen group was statistically significant farther from the fovea compared to control group, suggesting an alteration in macular pigment distribution in patients treated with Tamoxifen probably due to a reduction of macular pigment nearby the fovea.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×